Category: Research

Clinical Trials, Pharmaceuticals, Research

Sarclisa® (Isatuximab) Phase 3 Trial Shows Positive Results in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant

Sanofi announced today that the Phase 3 IMROZ trial evaluating Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) has successfully met its primary endpoint of progression-free survival (PFS) in transplant-ineligible patients with newly diagnosed multiple myeloma (MM). This groundbreaking outcome reinforces Sarclisa’s potential as a best-in-class medicine and marks a significant advancement in the treatment landscape for this patient population. Continue reading Sarclisa® (Isatuximab) Phase 3 Trial Shows Positive Results in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant

Ann Poorboy
Research

Proteomics Unlocks Advanced Cardiovascular Disease Prediction

Published October 20, 2023 Traditional methods of assessing the risk of atherosclerotic cardiovascular disease (ASCVD) have undergone a remarkable transformation. Now, the rise and fall of blood protein levels have emerged as an astonishingly accurate indicator of major ASCVD events, such as heart attacks. Kari Stefansson, M.D., Ph.D., CEO of deCODE Genetics, a subsidiary of Amgen, is leading the charge in revolutionizing how we approach … Continue reading Proteomics Unlocks Advanced Cardiovascular Disease Prediction

Ann Poorboy
Research

New Data on Ceftobiprole Revealed at US ID Week Congress 2023

Basilea Pharmaceutica Ltd, a renowned commercial-stage biopharmaceutical company (SIX: BSLN), continues to make significant strides in the battle against severe bacterial infections. The company recently unveiled groundbreaking data on its antibiotic ceftobiprole, marketed as Zevtera®, during the annual Infectious Disease Week (IDWeek) Congress 2023 held in Boston, Massachusetts. This new information bolsters the case for ceftobiprole’s efficacy against a wide range of clinically relevant pathogens, particularly methicillin-resistant Staphylococcus aureus (MRSA). Continue reading New Data on Ceftobiprole Revealed at US ID Week Congress 2023

Ann Poorboy
Leadership, Research

Jane Grogan: Bringing Determination to Biogen’s Research

Jane Grogan, Ph.D., a seasoned scientist with experience at biotech giants like Genentech, is embarking on a new adventure as she takes the helm of Biogen’s research unit. In her new role, which began officially on October 2, Grogan is eager to infuse the fast-paced, determined ethos of the biotech world into her new position. Continue reading Jane Grogan: Bringing Determination to Biogen’s Research

Ann Poorboy
Pharmaceuticals, Research

Massachusetts Biotechnology Thrives: Biopharma R&D and Biomanufacturing on the Rise

Massachusetts biotech and biopharma sectors continue to thrive, driven by a supportive environment, abundant resources, and strong venture capital backing. With a robust drug development pipeline and impressive acquisitions, Massachusetts remains a biotech hub of national and global significance. However, as the industry faces challenges, stakeholders are dedicated to sustaining this momentum. Continue reading Massachusetts Biotechnology Thrives: Biopharma R&D and Biomanufacturing on the Rise

Ann Poorboy
Research

First RNA Editing Therapy Nears Clinical Reality

As we await the data from the clinical trial application for WVE-006, the world holds its breath, knowing that this moment marks the transformation of medicine as we know it. RNA editing therapy has the potential to become a mainstream modality for treating diseases, even those that were historically challenging to address. The future is filled with possibilities, and hope stands at the forefront of this medical revolution. A brighter, healthier future beckons as RNA editing therapy takes center stage in the world of medicine. Continue reading First RNA Editing Therapy Nears Clinical Reality

Ann Poorboy
Research

Advancing Mastocytosis Research: A Swedish Observational Study

Mastocytosis, a complex and rare disease characterized by mast cell accumulation, presents a multitude of challenges for both patients and healthcare professionals. In Sweden, a pioneering cross-sectional observational study is set to shed light on the self-rated quality of life and disease-related symptoms in individuals diagnosed with systemic mastocytosis (SM). This groundbreaking research, initiated by Uppsala University, aims to provide critical insights into SM’s impact on patients’ lives. Continue reading Advancing Mastocytosis Research: A Swedish Observational Study

Ann Poorboy
Research

Mitochondrial Fatty Acid Oxidation in Pre-Eclampsia: Unveiling the Placental Connection

Pre-eclampsia is a complex and potentially life-threatening condition that affects a significant percentage of pregnancies worldwide. Its pathogenesis remains enigmatic, and despite its prevalence and potential risks to both mother and baby, effective treatments are still elusive. This article explores a groundbreaking study shedding light on a previously overlooked aspect of pre-eclampsia: mitochondrial fatty acid oxidation (FAO) in the placenta. The study aimed to compare the mRNA expression of key FAO enzymes in healthy pregnancies and various subgroups of pre-eclampsia, taking into account severity, onset time, and the presence of intrauterine growth restriction (IUGR). Continue reading Mitochondrial Fatty Acid Oxidation in Pre-Eclampsia: Unveiling the Placental Connection

Ann Poorboy
Research

Crossing Paths in Neurodegeneration: How Alzheimer’s Progress Is Paving the Way for Parkinson’s Research

Massive studies under the umbrella of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) bridge academia, industry and government research institutions. The Parkinson’s Progression Markers Initiative (PPMI), led by the Michael J. Fox Foundation, aims to achieve the same level of collaboration. In 2021, the consortium announced plans to triple enrollment numbers in its longitudinal clinical study. Continue reading Crossing Paths in Neurodegeneration: How Alzheimer’s Progress Is Paving the Way for Parkinson’s Research

Ann Poorboy